Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quemliclustat in metastatic pancreatic ductal adenocarcinoma
NCT06608927Phase 3Active, not recruiting
- Sponsor
- Arcus Biosciences
- Start
- Dec 2024
- Primary completion
- Nov 2030
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of quemliclustat in pancreatic ductal adenocarcinoma (PDAC), sponsored by Arcus Biosciences. Started Dec 2024; status: active, not recruiting.
02
Drugs
quemliclustat
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06608927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06608927.